207_Combined course Presentations

Triple negative

Subtypes according to clinical- pathological and genomic risk assessment

Treatment recommendation

De-escalation

Escalation

Ductal triple negative

pT1a node negative

No routine adjuvant chemotherapy for stage pT1a pN0. Dose-dense adjuvant chemotherapy preferred by only a

Neoadjuvant therapy for stage II or III is suggested as initial treatment approach. Chemotherapy should include anthracycline and taxanes

No consensus on post- neoadjuvant treatment in case of residual disease. In BRCA1/2 associated cancers, the Panel was evenly split on whether to recommend (neo)-adjuvant platinum chemotherapy though agreed that such patients should receive alkylating chemotherapy.

Higher T and N stage

minority of the consensus panel

33